Sharman, J. P., Farber, C. M., Mahadevan, D., Schreeder, M. T., Brooks, H. D., Kolibaba, K. S., . . . Burke, J. M. (2016). Ublituximab (TG‐1101), a novel glycoengineered anti‐CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: Results of a phase 2 trial. Br J Haematol.
シカゴスタイル引用形Sharman, Jeff P., et al. "Ublituximab (TG‐1101), a Novel Glycoengineered Anti‐CD20 Antibody, in Combination With Ibrutinib Is Safe and Highly Active in Patients With Relapsed And/or Refractory Chronic Lymphocytic Leukaemia: Results of a Phase 2 Trial." Br J Haematol 2016.
MLA引用形式Sharman, Jeff P., et al. "Ublituximab (TG‐1101), a Novel Glycoengineered Anti‐CD20 Antibody, in Combination With Ibrutinib Is Safe and Highly Active in Patients With Relapsed And/or Refractory Chronic Lymphocytic Leukaemia: Results of a Phase 2 Trial." Br J Haematol 2016.